Cite
HARVARD Citation
Neri, B. et al. (2013). Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single‐center experience with 31 patients. International journal of urology. pp. 478-483. [Online].